Metabolic dysfunction-associated steatohepatitis (MASH) is a complex and multifaceted condition with a heterogeneous patient population. Its high comorbidity with other metabolic conditions, such as metabolic syndrome, type 2 diabetes, and cardiovascular kidney metabolic syndrome, requires successful clinical research and care that adopts a holistic approach, considering the patient’s entire medical journey.
Read our guide for an in-depth discussion of essential MASH trial design factors, including:
- Early and ongoing patient engagement
- Multidisciplinary teams
- Patient education and support for disease management and trial retention